摘要
目的分析瑞格列奈应用于2型糖尿病治疗的疗效及安全性。方法选取2020年1月—2022年12月枣庄市皮肤病性病防治院收治的糖尿病患者70例,以数表法分为对照组和观察组,每组35例,分别以格列齐特和瑞格列奈进行治疗,从有效率、血糖相关指标、不良反应、血糖波动水平方面分析疗效。结果观察组治疗有效率较对照组高,达到了97.14%,差异有统计学意义(P<0.05)。在治疗前,两组各血糖指标相比,差异无统计学意义(P>0.05);治疗后,观察组各项血糖水平均低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率较对照组低,为8.57%,差异有统计学意义(P<0.05)。观察组24 h血糖波动值、餐后2 h血糖波动值较对照组低,差异有统计学意义(P<0.05)。结论瑞格列奈应用于2型糖尿病,可展现出较高的有效性和安全性,经治疗后,不仅可降低患者血糖指标,同时可以减少血糖的波动水平,有效维持病情的稳定,确保了患者的安全,是一种值得临床推荐的药物。
Objective To analyze the efficacy and safety of repaglinide in the treatment of type 2 diabetes mellitus.Methods 70 diabetic patients of Zaozhuang Dermatological and Venereal Disease Control Hospital from January 2020 to December 2022 were selected,and divided into the control group and the observation group by numerical method,and 35 patients in each group,treated with gliclazide and repaglinide,respectively.The efficacy was analyzed by the indexes of efficiency,blood glucose related indexes,adverse effects,and blood glucose fluctuation levels.Results The observation group had a higher treatment efficiency of 97.14%than control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the blood glucose indexes before treatment between two groups(P>0.05).After treatment,all blood glucose levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.57%,lower than that in the control group,and the difference was statistically significant(P<0.05).The observation group had lower blood glucose fluctuation values of 24 h and 2 h after meal compared with the control group,and the difference was statistically significant(P<0.05).Conclusion The application of repaglinide in type 2 diabetes can show high effectiveness and safety.After treatment,it can not only reduce the blood glucose index of patients,but also reduce the fluctuation level of blood glucose,effectively maintain the stability of the disease and ensure the safety of patients,which is a drug worthy of clinical recommendation.
作者
于海艳
韩瑜
丁文玲
YU Haiyan;HAN Yu;DING Wenling(Department of Pharmacy,Zaozhuang Dermatological and Venereal Disease Control Hospital,Zaozhuang,Shandong Province,277500 China)
出处
《糖尿病新世界》
2023年第11期81-83,87,共4页
Diabetes New World Magazine
关键词
瑞格列奈
2型糖尿病
疗效
安全性
血糖水平
血糖波动
Repaglinide
Type 2 diabetes mellitus
Efficacy
Safety
Blood glucose level
Blood glucose fluctuation
